BPC-157 vs TB-500: An Honest Evidence Comparison
BPC-157 has extensive animal data and a handful of small human studies; TB-500 has almost no direct evidence of its own, borrowing its reputation from its parent protein, thymosin beta-4. Neither is FDA-approved. An FDA advisory panel recommended both for compounding in July 2026; FDA has not decided.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed September 23, 2026 · Review policy
Quick answer
BPC-157 and TB-500 are both unproven in humans for recovery. BPC-157 has a large animal literature and a few small human studies. TB-500 has almost none of its own: FDA found no human studies of it, and the human trials people cite were of full-length thymosin beta-4, a different molecule. Neither is FDA-approved and both are banned in sport. In July 2026 an FDA advisory committee reportedly voted 8-6 to recommend each for the compounding list, against FDA staff advice; FDA has not made a final decision.
| BPC-157 | TB-500 | |
|---|---|---|
| Best studied for | Tendon, gut and tissue healing | Little direct study; parent protein TB4 studied for wound, cardiac and eye repair |
| Mechanism | Angiogenesis / VEGF, nitric oxide | Actin regulation / cell migration |
| Human evidence | Minimal (mostly animal) | None for TB-500 itself; early trials of parent peptide (TB4) |
| FDA status | Not approved; PCAC recommended for compounding list July 2026 (advisory, FDA decision pending) | Not approved; PCAC recommended for compounding list July 2026 (advisory, FDA decision pending) |
| Banned in sport | Yes (WADA) | Yes (WADA) |
| Main safety flag | Theoretical angiogenesis/tumor concern | Poorly characterized in humans |
Same category, slightly different evidence
BPC-157 and TB-500 are usually mentioned together as recovery peptides, and both share the same core problem: no confirmed benefit in humans. The distinction worth understanding is that TB-500 is a fragment of thymosin beta-4 (TB4), and TB4 itself reached early-phase human trials for wound, cardiac and corneal repair. The catch is that TB4's human trials tested the full 43-amino-acid protein, not the 7-amino-acid TB-500 fragment sold in the peptide market. FDA's 2026 review found no human studies of TB-500 itself, no animal studies of it for wound healing, and one lab study in which it had no effect. We grade both D (Preclinical Only).
Why the parent protein's data does not transfer
TB-500 is often marketed on the strength of TB4 research, but results for the full-length protein cannot be assumed for a small fragment, and the TB4 trials were early-phase, not confirmatory. By FDA's review of the actual substances, BPC-157 has somewhat more direct human data (a few small studies) than TB-500 (none). Neither compound has a completed randomized trial establishing recovery benefit in people, and neither is FDA-approved.
Safety and regulation
Both are prohibited in sport under WADA. Both were among seven peptides reviewed at the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. FDA staff recommended against listing either one, but the committee voted to recommend each, in votes reported as 8 to 6 with 1 abstention: BPC-157 for ulcerative colitis and TB-500 for wound healing. The vote is advisory. FDA must still decide and go through rulemaking before either could lawfully be compounded from bulk under 503A, and the uses reviewed did not include sports recovery. See our coverage of the vote.
BPC-157 carries a specific theoretical concern around angiogenesis in the context of existing tumors; TB-500's main issue is simply how little its human safety has been characterized. For either, the biggest practical risk is unregulated research-chemical supply of unverified purity.
Bottom line
Neither is proven in humans for recovery. On evidence for the actual molecule, BPC-157 is slightly ahead: it has small human studies, while TB-500 has none and relies on research into its parent protein. Both are unapproved and banned in sport. Both received a non-binding advisory vote in favor of compounding in July 2026, so their legal status depends on a future FDA decision. Stacking them combines two unproven compounds.
Frequently asked questions
Is BPC-157 or TB-500 better for healing?+
Neither is proven in humans. BPC-157 has more direct evidence (animal studies and a few small human studies); TB-500 has almost none of its own and relies on research into its parent protein, thymosin beta-4. There is no completed human trial establishing either as an effective recovery treatment.
Can you take BPC-157 and TB-500 together?+
They are frequently stacked in community protocols, but that combines two compounds that are both unproven in humans and not FDA-approved. Any use should involve a licensed clinician, not research-chemical vendors.
Are BPC-157 and TB-500 legal?+
Neither is FDA-approved, and neither is on the FDA's 503A Bulks List today. An FDA advisory committee recommended both for that list in July 2026, but the vote is not binding and FDA has not acted. Both are sold as 'research use only' chemicals, which is not a lawful route to human use, and both are banned in sport.
Sources
- 1.July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee · U.S. Food & Drug Administration
- 2.FDA briefing document: BPC-157, Pharmacy Compounding Advisory Committee (July 2026) · U.S. Food & Drug Administration
- 3.FDA briefing document: TB-500, Pharmacy Compounding Advisory Committee (July 2026) · U.S. Food & Drug Administration
- 4.NPR coverage of the July 23, 2026 PCAC peptide vote · NPR
- 5.WADA Prohibited List · World Anti-Doping Agency